BackArrowhead Pharmaceuticals Overview
Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Target Price

Analysts' average 12-month price target for Arrowhead Pharmaceuticals is $110.

Get informed when a big investor buys or sells

+ Follow

Share Price

$64.19

Average Target Price

$108.0068.3% upside

9 analysts in the last 4 months

High: $126 | Low: $74

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-24Goldman SachsAndrea Newkirk$7415.3% upsideOpen
2026-08-31RBC CapitalLuca Issi$10055.8% upsideOpen
2026-08-06H.C. Wainwright$12086.9% upsideOpen
2026-08-05Stifel Nicolaus$10462% upsideOpen
2026-07-27H.C. Wainwright$11579.2% upsideOpen
2026-07-23Morgan Stanley$12086.9% upsideOpen
2026-07-23Piper SandlerEdward Tenthoff$12696.3% upsideOpen
2026-07-22Chardan CapitalKeay Nakae$11579.2% upsideOpen
2026-07-13Stifel NicolausJames Condulis$9852.7% upsideOpen
2026-05-13Bernstein$4628.3% downsideOpen
2026-05-08Chardan Capital$9040.2% upsideOpen
2026-04-21Morgan Stanley$10055.8% upsideOpen
2026-02-06Morgan Stanley$7821.5% upsideOpen
2026-01-27Robert W. Baird$8126.2% upsideOpen
2026-01-21H.C. Wainwright$10055.8% upsideOpen
2026-01-13UBS$11071.4% upsideOpen
2026-01-13Piper Sandler$11071.4% upsideOpen
2026-01-07Morgan Stanley$8126.2% upsideOpen
2026-01-07Chardan Capital$8024.6% upsideOpen
2026-01-02Tudor PickeringWilliam Pickering$3545.5% downsideOpen
2025-12-31Bernstein$3545.5% downsideOpen
2025-12-17Piper SandlerEdward Tenthoff$10055.8% upsideOpen
2025-12-11RBC Capital$8024.6% upsideOpen
2025-12-02H.C. Wainwright$8532.4% upsideOpen
2025-11-26Morgan Stanley$4825.2% downsideOpen
2024-11-29BernsteinWilliam Pickering$2462.6% downsideOpen
2024-11-27Loop Capital MarketsKeay Nakae$29.9753.3% downsideOpen
2024-09-03CitigroupDavid Lebowitz$2757.9% downsideOpen
2024-07-05H.C. WainwrightPatrick Trucchio$29.9753.3% downsideOpen
2024-06-05Goldman SachsAndrea Tan$3151.7% downsideOpen
2024-05-30RBC CapitalLuca Issi$24.9861.1% downsideOpen
2023-02-07RBC Capital$38.4640.1% downsideOpen
2023-02-07Piper Sandler$5219% downsideOpen
2022-12-06H.C. Wainwright$44.9630% downsideOpen
2022-11-29Jefferies$37.4741.6% downsideOpen
2022-11-29Morgan Stanley$3742.4% downsideOpen
2022-11-29Leerink Partners$3151.7% downsideOpen
2022-01-19Goldman SachsMadhu Kumar$8532.4% upsideOpen

Arrowhead Pharmaceuticals (ARWR) FAQ

Arrowhead Pharmaceuticals posts a target price of $110. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $110 for ARWR means covering analysts, on average, see the stock 68.3% upside of $64.19 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for ARWR's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Arrowhead Pharmaceuticals's other metric pages and overview cover the third.

Judging Arrowhead Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $110 here, then scan peer and history charts to see if the gap is persistent.